Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Discontinued in 2005. Continued as Endocrine, Metabolic & Immune Disorders - Drug Targets (1871-5303). Current Drug Targets - Immune, Endocrine & Metabolic Disorders aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in immune, endocrine and metabolic disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in immune, endocrine and metabolic disorders. As the discovery, identification, characterization and validation of novel human drug targets for immune, endocrine and metabolic drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Further information
- Category Links